Keyphrases
Overall Survival
100%
Prescription Drugs
100%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
100%
Charlson Comorbidity Index
60%
Medication Classes
60%
Body Mass Index
40%
Prostate-specific Antigen
40%
New Therapies
40%
Comorbid Diseases
40%
Number of Medications
40%
Prostate Cancer Patients
40%
Confidence Interval
20%
Initial Treatment
20%
Disease Burden
20%
Year of Diagnosis
20%
Adjusted Hazard Ratio
20%
Prognosticate
20%
Risk Stratification
20%
Multivariable Logistic Regression
20%
Treatment Decisions
20%
Advanced Prostate Cancer
20%
Increased Mortality
20%
Enzalutamide
20%
Cox Proportional Hazards Modeling
20%
US Veterans
20%
Treatment Selection
20%
Patient-independent
20%
Abiraterone
20%
Medicine and Dentistry
Overall Survival
100%
Prostate Cancer
100%
Prescription Medication
100%
Medicine
50%
Body Mass Index
33%
Prostate Specific Antigen
33%
Charlson Comorbidity Index
33%
Diseases
33%
Cardiovascular System
16%
Hazard Ratio
16%
Disease Burden
16%
Logistic Regression Analysis
16%
Retrospective Study
16%
Abiraterone
16%
Enzalutamide
16%
Comorbidity
16%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Overall Survival
100%
Prescription Medication
100%
Comorbidity
50%
Diseases
50%
Prostate Specific Antigen
33%
Retrospective Study
16%
Enzalutamide
16%
Abiraterone
16%